New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
16:37 EDTNAVBNavidea refocuses resources to align funding of pipeline, names interim CEO
The Board of Directors of Navidea Biopharmaceuticals announced that it is refocusing the company's resources to better align the funding of the pipeline programs with the expected growth in Lymphoseek revenue. To facilitate the refocusing effort, the Board has asked Michael Goldberg, M.D. to serve as interim CEO while a search for a new CEO is conducted. The Navidea Board believes that the market is not currently giving appropriate value to its Phase III pipeline products and is likely penalizing the company for allocating resources to these exciting programs. The company is also working to establish new sources of non-dilutive funding, including collaborations that can augment the balance sheet as the company works to reduce spending to levels that can be more closely offset by growing Lymphoseek revenue. In particular, substantial progress on the Manocept platform has resulted in some very exciting partnering opportunities that will further expand the company's pipeline while requiring much less funding than the two ongoing Phase III programs. Dr. Mark Pykett has agreed to step down from the CEO position, effective on or about May 31, to work full time on maximizing the potential of the Manocept program. Dr. Pykett will also continue to serve as a Director of Navidea until the 2014 Annual Meeting. Navidea remains committed to expanding the Lymphoseek label and realizing the full potential of the product. It intends to work closely with its partners to continue the strong growth of this important product. The company believes that the resources being devoted to drive Lymphoseek sales will eventually provide returns to the point where developmental stage programs can be substantially funded from cash flow from operations. The company is focused on expanding the market for Lymphoseek in all relevant markets. To this end, the Compensation, Nominating and Governance Committee of the Board of Directors has initiated a search for a CEO who will bring experience in global product sales, especially related to expanding the market for commercial products.
News For NAVB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 3, 2015
07:32 EDTNAVBNavidea awarded $1.8M grant for evaluation of Manocept agent in Kaposi's Sarcoma
Subscribe for More Information
September 2, 2015
07:33 EDTNAVBNavidea announces dual listing on Tel Aviv Stock Exchange
Navidea Biopharmaceuticals announced that the Tel Aviv Stock Exchange has approved the new listing of Navidea's common stock on the TASE beginning on Tuesday, September 8 under the ticker symbol NAVB. The company's common stock will be listed on both the NYSE MKT in the United States and the TASE in Israel. The company also announced that, based upon Navidea's current market capitalization, it expects its shares to be subject to inclusion in five TASE equity indexes.
07:27 EDTNAVBSidoti to hold a conference
2015 Sidoti Emerging Growth Conference is being held in New York on September 2.
August 24, 2015
07:32 EDTNAVBNavidea to register shares for dual listing on TASE
Navidea Biopharmaceuticals announced that it has filed an application for registration of shares of its common stock for dual listing on the Tel-Aviv Stock Exchange, or TASE. Dual listing on the TASE is allowed in the U.S. and Israel without any additional regulatory requirements for companies whose shares are listed on certain accredited stock exchanges outside of Israel, including the NYSE MKT.
August 20, 2015
07:31 EDTNAVBNavidea reports publication of Lymphoseek comparative results in pain study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use